SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC increased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 31.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,883 shares of the company's stock after buying an additional 5,503 shares during the period. ProShare Advisors LLC's holdings in SpringWorks Therapeutics were worth $827,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Huntington National Bank increased its stake in shares of SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock valued at $25,000 after buying an additional 192 shares during the period. AlphaQuest LLC grew its stake in SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after purchasing an additional 414 shares during the last quarter. Barclays PLC grew its stake in SpringWorks Therapeutics by 0.3% in the fourth quarter. Barclays PLC now owns 156,123 shares of the company's stock valued at $5,641,000 after purchasing an additional 447 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in SpringWorks Therapeutics by 7.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock valued at $327,000 after purchasing an additional 622 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in SpringWorks Therapeutics by 2.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,013 shares of the company's stock valued at $1,591,000 after purchasing an additional 931 shares during the last quarter.

SpringWorks Therapeutics Price Performance

NASDAQ SWTX traded down $0.02 during trading on Tuesday, hitting $46.46. The company's stock had a trading volume of 3,690,748 shares, compared to its average volume of 2,180,322. The company has a market cap of $3.50 billion, a PE ratio of -13.35 and a beta of 0.77. The business's 50 day simple moving average is $43.49 and its 200-day simple moving average is $42.92. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The business had revenue of $49.09 million during the quarter, compared to analyst estimates of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. Analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the completion of the sale, the chief executive officer now owns 954,869 shares of the company's stock, valued at $51,792,094.56. The trade was a 4.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Badreddin Edris sold 20,000 shares of SpringWorks Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now directly owns 169,712 shares of the company's stock, valued at $9,203,481.76. This trade represents a 10.54% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.83% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Cowen lowered SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. TD Cowen reiterated a "hold" rating and issued a $47.00 target price (down previously from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Wedbush reiterated a "neutral" rating and issued a $47.00 target price (down previously from $81.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Evercore ISI lowered SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. Finally, Guggenheim reiterated a "neutral" rating and issued a $47.00 target price on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Seven equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, SpringWorks Therapeutics has a consensus rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.